ClinicalTrials.gg
Active, not recruitingNCT05835128Updated Sep 29, 2023

Assessment of Long-term Sequelae of Coronavirus Disease 2019 (COVID-19) Pneumonia With Chest CT and Pulmonary Function Tests

An observational study in COVID-19 Pneumonia, Sequelae of; Infection and Respiratory Function Impaired, sponsored by Centro Hospitalar Universitario do Algarve. Active, not recruiting at 2 sites in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-29.

Primary conditionCOVID-19Registry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's listed conditions name COVID-19, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centro Hospitalar Universitario do Algarve · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in COVID-19 with a site in Portugal — 9 open to participants now, 11 under way, 2 of them phase 3. COVID-19 · Portugal.

Planned enrollment
15th of 20
250 · median 699
Started
2020
with 14 others
Observational
20 of 38
6 open now
Primary completion
2024-12
later than 3 of 10 live
Registered
35th of 38
by date
Lead sponsor
2 of 38
Centro Hospitalar Universitario do Algarve

Among the 38 studies in COVID-19 with a site in Portugal, this one is the 15th largest by planned enrollment of the 20 observational ones that give a count, is one of 15 that started in 2020, is one of 20 observational ones, reaches primary completion later than 3 of the 10 other live ones, and was the 35th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

9 of the 38 studies in COVID-19 with a site in Portugal are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in COVID-19 with a site in Portugal, or all of them as a file.
02

Study summary

The goal of this prospective multicentric study is to evaluate the presence of long-term pulmonary sequelae in patients who had required hospitalization for treating COVID-19 pneumonia, trough chest CT and pulmonary function tests (PFT).

Secondly we would like to evaluate the possible correlation between the chest CT findings and pulmonary function tests pre-existing co-morbidities and type of therapy used during hospitalization.

Read the detailed description

The investigators will invite to participate in this study patients who had been hospitalized with positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) , namely with positive reverse transcription polymerase chain reaction or positive rapid antigen test, and with respiratory insufficiency (at admission or developed during hospital stay), or with viral pneumonia documented with thorax x-ray or Chest CT, during the period between march 2020 and march 2022.

Patients who agree to participate and sign the informed consent will be enrolled in the study.

Participants will be evaluate in two different periods: approximately 4 to 6 months after hospital discharge and approximately 12 to 14 months after hospital discharge.

The first evaluation includes a physical examination at medical post-COVID-19 consultation, pulmonary function tests and reduced dose chest CT.

The second evaluation includes a physical examination at medical post-COVID-19 consultation, and will include reduced dose chest CT and pulmonary function tests only if there were significative findings on those exams on the first evaluation, or if there are any clinical significative findings at the present moment.

All the evaluations must respect the following time intervals: the pulmonary function tests and the chest CT will be done within a 6 week maximum interval of each other, and both of these examinations will be done within a 8 week maximum interval regarding the clinical evaluation.

Demographic and clinical data will be collected by qualified clinical study staff (i.e., by physicians who conduct the post-COVID-19 medical consultation) and the patient will given the EuroQol 5 Dimension 5 Level questionnaire (EQ-5D-3L) to assess the health status.

The reduced dose Chest CT will be obtained with the patient in a supine position and with breath-holding following inspiration, in a spiral acquisition mode with a 1 ,5 mm slice thickness and the images will be reviewed by four senior radiologist blinded to clinical and respiratory functional tests results.

The pulmonary function tests will be interpreted according to the American Thoracic Society and European Respiratory Society guidelines 2022. The parameters measured included the forced expiratory flow between 25% and 75% of forced vital capacity (FVC), forced expiratory volume (FEV1), FVC/FEV1, vital capacity, total lung capacity, residual volume and the diffusing capacity of lung for carbone monoxide (DLCO), DLCO/Alveolar Volume (AV).

03

Conditions studied

  • COVID-19 Pneumonia
  • Sequelae of; Infection
  • Respiratory Function Impaired
  • SARS CoV 2 Infection
  • SARS-CoV 2 Pneumonia

Keywords

  • COVID-19
  • Tomography
  • Infections, Viral
  • Respiratory Tract Infections
  • Virus Disease
  • Coronavirus Infections
  • Infections
  • Lung Diseases
  • RNA virus infections
  • Respiratory tract diseases
  • Chest CT
  • Reduced dose chest CT
  • Lung CT
  • coronaviridae infections
  • lung sequela
  • pneumonia
  • respiratory function tests
  • follow-up studies
  • multicentric studies
  • prospective studies
04

In context

COVID-19 Reclassified

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

This study's planned enrollment of 250 is close to the median of 268 across 3,209 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Centro Hospitalar Universitario do Algarve is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will be conducted in two Portuguese hospitals from the same institution (university center). Patients will be recruited from the follow -up Post-COVID-19 medical consultations. All patients attending these follow- up consultations will be invited to participate and enrolled if they agree to sign the written informed consent (following the ethics committee protocol).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • at least 18 years old of age;
  • positive SARS-CoV-2 reverse transcription-polymerase chain reaction on a nasopharyngeal and/or oropharyngeal swab or positive SARS-CoV-2 rapid antigen test
  • hospitalization in one of two hospitals of our institution (university center) in consequence of SARS-CoV-2 related disease between march of 2020 and march of 2022 and having :
  • respiratory insufficiency when admitted or developing after admission or image documented viral pneumonia ;
  • at least one thorax x-ray or lung CT acquired during the hospitalization period

Exclusion criteria

Exclusion Criteria:

  • previous lung cancer
  • previous intersticial lung disease
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No
07

What researchers measure

Primary outcomes

  1. Prevalence of structural lung sequelae after COVID-19 pneumonia

    evaluate the presence of lung structural sequelae with chest CT

    Time frame: 12 -14 months

  2. Prevalence of functional lung impairment after COVID-19 pneumonia

    evaluate the presence of impaired PFT after COVID-19 pneumonia

    Time frame: 12 -14 months

  3. Association between chest CT findings and PFT impairment after COVID-19 pneumonia

    evaluate the possible correlation between the presence of pulmonary structural alterations on chest CT and the presence of impaired PFT

    Time frame: 12-14 months

Secondary outcomes

  1. Prevalence of structural lung sequelae after COVID-19 pneumonia

    evaluate the presence of lung structural sequelae with chest CT

    Time frame: 4-6 months

  2. Prevalence of functional lung impairment after COVID-19 pneumonia

    evaluate the presence of impaired PFT after COVID-19 pneumonia

    Time frame: 4-6 months

  3. Association between chest CT findings and PFT impairment after COVID-19 pneumonia

    evaluate the possible correlation between the presence of pulmonary structural alterations on chest CT and the presence of impaired PFT

    Time frame: 4-6 months

  4. Association between chest CT findings after COVID-19 pneumonia and therapy used during hospitalization

    to evaluate if there is any association between the presence of lung structural sequelae on chest CT and the different treatments used during hospitalization (corticotherapy, oxygen therapy, mechanical ventilation)

    Time frame: 4-6 months

  5. Association between chest CT findings after COVID-19 pneumonia and therapy used during hospitalization

    to evaluate if there is any association between the presence of lung structural sequelae on chest CT and the different treatments used during hospitalization (corticotherapy, oxygen therapy, mechanical ventilation)

    Time frame: 12-14 months

  6. Association between chest CT findings after COVID-19 pneumonia and pre-existing co-morbidities

    to evaluate if there is any association between the presence of lung structural sequelae on chest CT and pre-existing co-morbidities (diabetes, asthma, hypertension, dyslipidaemia, obesity, chronic obstructive pulmonary disease, cigarette smoking, heart disease and kidney disease)

    Time frame: 4-6 months

  7. Association between chest CT findings after COVID-19 pneumonia and pre-existing co-morbidities

    to evaluate if there is any association between the presence of lung structural sequelae on chest CT and pre-existing co-morbidities (diabetes, asthma, hypertension, dyslipidaemia, obesity,, chronic obstructive pulmonary disease, cigarette smoking, heart disease and kidney disease)

    Time frame: 12 -14 months

08

Study locations

2 sites
  • Hospital de Faro (CHUA)
    Faro, 8005, Portugal
  • Hospital de Portimâo (CHUA)
    Portimão, 8500-338, Portugal
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Dec 2024, 57 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 57 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
Apr 28, 2023
StartActual
Mar 1, 2020
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05835128
Lead sponsor
Centro Hospitalar Universitario do Algarve
Collaborators
Universidade do Algarve
Responsible party
Mónica Diniz, MD (Principal Investigator, Centro Hospitalar Universitario do Algarve) — Principal investigator
First posted
Apr 28, 2023
Start date
Mar 1, 2020
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Sep 29, 2023

Study contacts

Mónica Diniz, MD
principal investigator · unafilliated
Castro Miguel, MD
principal investigator · Centro Hospitalar Universitário do Algarve/Polo de Portimão

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion